IL92234A - Pharmaceutical compositions containing ganciclovir and granulocyte macrophage colony stimulating factor for treatment of myelosuppression associated with acquired immune deficiency - Google Patents

Pharmaceutical compositions containing ganciclovir and granulocyte macrophage colony stimulating factor for treatment of myelosuppression associated with acquired immune deficiency

Info

Publication number
IL92234A
IL92234A IL92234A IL9223489A IL92234A IL 92234 A IL92234 A IL 92234A IL 92234 A IL92234 A IL 92234A IL 9223489 A IL9223489 A IL 9223489A IL 92234 A IL92234 A IL 92234A
Authority
IL
Israel
Prior art keywords
treatment
pharmaceutical compositions
compositions containing
stimulating factor
colony stimulating
Prior art date
Application number
IL92234A
Other languages
English (en)
Other versions
IL92234A0 (en
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL92234A0 publication Critical patent/IL92234A0/xx
Publication of IL92234A publication Critical patent/IL92234A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL92234A 1988-11-09 1989-11-07 Pharmaceutical compositions containing ganciclovir and granulocyte macrophage colony stimulating factor for treatment of myelosuppression associated with acquired immune deficiency IL92234A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26927688A 1988-11-09 1988-11-09

Publications (2)

Publication Number Publication Date
IL92234A0 IL92234A0 (en) 1990-07-26
IL92234A true IL92234A (en) 1993-06-10

Family

ID=23026570

Family Applications (1)

Application Number Title Priority Date Filing Date
IL92234A IL92234A (en) 1988-11-09 1989-11-07 Pharmaceutical compositions containing ganciclovir and granulocyte macrophage colony stimulating factor for treatment of myelosuppression associated with acquired immune deficiency

Country Status (11)

Country Link
EP (2) EP0446230A1 (xx)
JP (1) JPH0651639B2 (xx)
KR (1) KR960014097B1 (xx)
AU (1) AU630637B2 (xx)
CA (1) CA2002413A1 (xx)
DK (1) DK82191D0 (xx)
IL (1) IL92234A (xx)
MY (1) MY105868A (xx)
NZ (1) NZ231304A (xx)
WO (1) WO1990004973A1 (xx)
ZA (1) ZA898478B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020835A1 (en) * 1992-04-14 1993-10-28 Schering Corporation Treatment of hepatitis with gm-csf
JPH09509828A (ja) * 1994-03-04 1997-10-07 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 標的遺伝子損傷をした動物
US5585355A (en) * 1994-04-22 1996-12-17 Alkermes, Inc. Method for increasing blood-ocular barrier permeability with permeabilizer peptides
DE19802375A1 (de) * 1998-01-22 1999-07-29 Schenk Filterbau Gmbh Verfahren zur Entfernung und/oder Inaktivierung von Viren
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE79761T1 (de) * 1985-11-27 1992-09-15 Genetics Inst Behandlung einer krankheit vom aids-typ.
US4808611A (en) * 1986-07-30 1989-02-28 Immunex Corporation Use of interleukin-1 to induce development of multipotent hemopoietic cell populations

Also Published As

Publication number Publication date
JPH04500210A (ja) 1992-01-16
NZ231304A (en) 1997-05-26
DK82191A (da) 1991-05-03
EP0446230A1 (en) 1991-09-18
AU630637B2 (en) 1992-11-05
MY105868A (en) 1995-02-28
EP0370656A1 (en) 1990-05-30
ZA898478B (en) 1990-07-25
CA2002413A1 (en) 1990-05-09
AU4526889A (en) 1990-05-28
IL92234A0 (en) 1990-07-26
WO1990004973A1 (en) 1990-05-17
DK82191D0 (da) 1991-05-03
JPH0651639B2 (ja) 1994-07-06
KR900701301A (ko) 1990-12-01
KR960014097B1 (ko) 1996-10-14

Similar Documents

Publication Publication Date Title
IL98070A0 (en) Muteins of the granulocyte colony stimulating factor(g-csf)and pharmaceutical compositions containing them
GB2193631B (en) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
ZA836222B (en) Compositions and their use in the production of dental restorations
GR861825B (en) Complexes of flavanolignanes with phospholipids preparation thereof and associated pharmaceutical compositions
IL84946A0 (en) Drug delivery compositions and their preparation
AR243240A1 (es) Procedimiento para preparar una proteina con actividad de factor estimulador de colonia y acido nucleico que comprende una secuencia nucleotidica capaz de modificarla.
IL92138A0 (en) Pharmaceutical compositions containing piroxicam and their preparation
IL88989A0 (en) 16-dehydro-vitamin d3 derivatives their preparation and pharmaceutical compositions containing them
PT78986B (en) Coumarin derivatives pharmaceutical compositions containing the same and use thereof in the treatment of cancer
GB2223225B (en) Neutrophil-activating factor: its production and use in treatment
IL92234A (en) Pharmaceutical compositions containing ganciclovir and granulocyte macrophage colony stimulating factor for treatment of myelosuppression associated with acquired immune deficiency
NZ214702A (en) Using interferon in treatments and pharmaceutical compositions
GB8808758D0 (en) Nutritional and medicinal compositions
ZA875268B (en) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
EP0280593A3 (en) Composition on the basis of an amino-acid and vitamins for use in cancer therapy
IL91451A0 (en) Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction
GB2201171B (en) Compositions for use in the treatment of cellulosic materials and their preparation
AU8313187A (en) Pharmaceutical composition of colony stimulating factor-i and granulocyte colony stimulating factor
GB2221464B (en) Oxaza heterocycles and their use in pharmaceutical compositions
GB2213821B (en) Synthetic human granulocyte colony stimulating factor gene
NZ224307A (en) Preparation of purine derivatives and pharmaceutical compositions
EP0289997A3 (en) Coating composition and its use in the preparation of multi-layer coatings
GB2207050B (en) Parenteral delivery of drugs and compositions for use therein
IL86844A (en) Compositions with controlled zero-order delivery rate and their preparation
AU3980693A (en) New pharmaceutical compositions and new pharmaceutical products allowing the regeneration of leukocytes and their use in the treatment of acquired immuno-deficient syndrom

Legal Events

Date Code Title Description
RH Patent void